Lithera reports Phase IIb data for LIPO-202

Lithera Inc. (San Diego, Calif.) reported data on Monday from the Phase IIb RESET trial evaluating LIPO-202 -- a subcutaneous formulation of the long-acting adrenergic receptor beta 2 agonist (LABA) s...